Drug intelligence / Profile preview

Zentius D

Development stage: Unknown
Lead developer: ITF Ilaç San. ve Tic. Ltd. Şti.
Modality: Small Molecules
Administration: Oral

Overview

Zentius D is a combination pharmaceutical product and nutritional supplement containing calcium carbonate and cholecalciferol (vitamin D3). It is developed and marketed by ITF İlaç Sanayi ve Ticaret, the Turkish subsidiary of Italfarmaco, and is manufactured by Italfarmaco S.p.A. Each chewable tablet contains 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 400 IU of vitamin D3. The product is indicated for the prevention and treatment of calcium and vitamin D deficiencies, particularly in the elderly, and as an adjunct to specific osteoporosis treatments. Calcium is essential for bone formation and maintenance, while vitamin D3 enhances the intestinal absorption of calcium and regulates bone mineralization.

Brand names: Zentius D

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Zentius D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zentius D.

Explore the full profile